Objective: To investigate the effect of seabuckthorn fruit on the proliferation and migration of lung cancer A549 cells by network pharmacology and in vitro experiments, and to explore the related mechanism. Methods: The effective components and drug targets of seabuckthorn fruit were screened by searching TCMSP database, GeneCard database and OMIM database to obtain lung cancer targets. The intersection targets of drugs and diseases were obtained by using the micro-bioinformatics platform, and then imported into the STRING website to construct the PPI network. The core target network diagram and drug-disease-target network were constructed by Cytoscape 3.10.3 software. GO and KEGG enrichment analysis was performed on the intersection targets using the Metascape database. Molecular docking visualization was performed using Discovery Studio. CCK-8 and cell scratch experiments were used to evaluate the inhibitory effect of seabuckthorn-containing serum on the proliferation and migration of lung cancer A549 cells. Results: The results of network pharmacology analysis showed that a total of 8 effective active ingredients were screened out, corresponding to 85 key targets for the prevention and treatment of lung cancer. Among them, molecular docking experiments confirmed that MMP9, CDK4, MMP2, EGFR, HIF1A and CYP1B1 targets closely related to tumor cell proliferation and metastasis had good binding activity with quercetin, isorhamnetin, kaempferol and stigmasterol. In vitro experiments showed that 10% seabuckthorn fruit-containing serum could inhibit the proliferation of A549 cells and reduce the wound healing rate after 24 h. Conclusion: Seabuckthorn fruit has a potential preventive and therapeutic effect on lung cancer, which can inhibit the proliferation and migration of A549 cells.
ZHANG Lingyu
,
YANG Xuewen
,
JIN Ziqi
,
XUE Yongzhi
. Exploring the effect of seabuckthorn fruit on the proliferation and migration of lung cancer A549 cells based on network pharmacology[J]. Journal of Baotou Medical College, 2026
, 42(4)
: 1
-7
.
DOI: 10.16833/j.cnki.jbmc.2026.04.001
[1] Miller M, Hanna N. Advances in systemic therapy for non-small cell lung cancer[J]. BMJ, 2021, 375: n2363.
[2] Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends[J]. Nat Rev Clin Oncol, 2023, 20(9): 624-639.
[3] Xu D, Yuan L, Meng F, et al. Research progress on antitumor effects of sea buckthorn, a traditional Chinese medicine homologous to food and medicine[J]. Front Nutr, 2024, 11: 1430768.
[4] Nogales C, Mamdouh ZM, List M, et al. Network pharmacology:curing causal mechanisms instead of treating symptoms[J]. Trends Pharmacol Sci, 2022, 43(2): 136-150.
[5] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
[6] 李畅, 王浩, 贺千羽, 等. 槲皮素通过诱导铁死亡抑制A549细胞增殖的作用及机制研究[J]. 中草药, 2022, 53(22): 7112-7120.
[7] 文兰香, 覃世运, 陈丽君. 槲皮素调控AMPK/mTOR通路对肺癌A549细胞自噬的影响[J]. 中国免疫学杂志, 2020, 36(19): 2375-2379.
[8] 吴洪皓, 杨华, 吴鹏. 槲皮素对A549细胞PI3K/Akt信号通路及肿瘤恶性特征的调控机制[J]. 中成药, 2021, 43(12): 3476-3479.
[9] 李华洋, 许婧, 那辉, 等. 槲皮素通过STAT3信号通路抑制肺癌A549细胞迁移和侵袭[J]. 国际药学研究杂志, 2017, 44(3): 262-266.
[10] 靳莉, 张小红, 胡朝阳, 等. 槲皮素对人肺癌A549细胞移植瘤模型小鼠移植瘤生长和肺转移及细胞侵袭和迁移的影响及其机制[J]. 吉林大学学报(医学版), 2023, 49(4): 1018-1026.
[11] Zhai T, Zhang X, Hei Z, et al. Isorhamnetin inhibits human gallbladder cancer cell proliferation and metastasis via PI3K/AKT signaling pathway inactivation[J]. Front Pharmacol, 2021, 12: 628621.
[12] Luo W, Liu Q, Jiang N, et al. Isorhamnetin inhibited migration and invasion via suppression of Akt/ERK-mediated epithelial-to-mesenchymal transition (EMT) in A549 human non-small-cell lung cancer cells[J]. Biosci Rep, 2019, 39(9): BSR20190159.
[13] 于春, 马学莉, 马燕花. 豆甾醇抗肿瘤作用机制的研究进展[J]. 华西药学杂志, 2024, 39(6): 737-740.
[14] 张敬, 史晓宇, 孟玮, 等. 山萘酚通过下调ERRα抑制非小细胞肺癌A549细胞的侵袭和迁移[J]. 中国肿瘤生物治疗杂志, 2018, 25(12): 1230-1236.
[15] 王洪凯, 唐浩, 朱世达, 等. IL-17A通过PI3K/Akt通路促进肺癌A549细胞的增殖、迁移和侵袭[J]. 现代肿瘤医学, 2023, 31(13): 2384-2388.
[16] 黄倩, 张瀚涛, 张晓笛, 等. 基于网络药理学探讨西黄丸通过EGFR/AKT/P65信号通路抑制肺癌A549细胞侵袭转移的作用[J]. 中医药导报, 2024, 30(6):1-9, 28.
[17] JouidaA, McCarthy C, Fabre A, et al. Exosomes:a new perspective in EGFR-mutated lung cancer[J]. Cancer Metastasis Rev, 2021, 40(2): 589-601.
[18] Zhou F, Guo H, Xia Y, et al. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer[J]. Nat Rev Clin Oncol, 2025, 22(2): 95-116.
[19] D′Uva G, Baci D, Albini A, et al. Cancer chemoprevention revisited: cytochrome P450 family 1B1 as a target in the tumor and the microenvironment[J]. Cancer Treat Rev, 2018, 63:1-18.
[20] 刘不悔, 王美子, 孙伟, 等. 低氧诱导因子的分子调控机制及中药的干预作用[J]. 中国中药杂志, 2020, 45(20): 4805-4811.
